Pfiz­er gives in­ter­im up­date on PARP in­hibitor com­bo treat­ment, earns pri­or­i­ty re­view at FDA

The com­bi­na­tion of prostate can­cer drug Xtan­di and Talzen­na, a PARP in­hibitor, re­duced the risk of death or dis­ease pro­gres­sion in metasta­t­ic prostate can­cer pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER